healthX FY26 revenue rose 20%, operating cash outflow widened
Key highlights
- healthX FY26 revenue from operations rose 20.0% to Rs 1,305.9 crore from Rs 1,088.1 crore in FY25.
- healthX FY26 gross margin increased to Rs 97.5 crore, and gross-margin percentage rose to 7.5% from 6.5%.
- healthX used Rs 73.8 crore in operating activities in FY26, compared with Rs 17.3 crore used in FY25.
- healthX ended FY26 with Rs 22.1 crore of borrowings and Rs 30.2 crore of cash and cash equivalents.
powered by IRIS

Health X Platform Limited, referred to as healthX, increased FY26 revenue 20.0% to Rs 1,305.9 crore, but net cash used in operating activities widened to Rs 73.8 crore from Rs 17.3 crore in FY25. The sales recovery followed FY25’s decline, while negative operating profit and a working-capital outflow kept operating cash flow below zero.
Know Health X Platform inside out
Results, valuation, peers and who's buying, in one view.
How did healthX revenue and gross margin change in FY26?
healthX increased revenue from operations by Rs 217.8 crore, or 20.0%, to Rs 1,305.9 crore in FY26 from Rs 1,088.1 crore in FY25. The result reversed the FY25 decline, when revenue fell from Rs 1,355.2 crore in FY24. FY26 revenue nevertheless remained Rs 49.3 crore below the FY24 level.
The recovery extended through FY26 rather than being confined to the final quarter. Revenue rose from Rs 279 crore in Q1 FY26 to Rs 308 crore in Q2, Rs 341 crore in Q3 and Rs 378 crore in Q4. Q4 FY26 revenue was Rs 96 crore above Rs 282 crore in Q4 FY25, whereas Q1 FY26 was Rs 16 crore above the comparable FY25 quarter.
Earnings before interest, tax, depreciation and amortisation, or EBITDA, remained negative in all three years shown below, despite the FY26 increase in revenue and gross margin.
healthX’s gross margin rose by Rs 26.8 crore to Rs 97.5 crore in FY26, while the gross-margin percentage increased by 1.0 percentage point to 7.5% from 6.5% in FY25. Cost of materials consumed rose to Rs 1,208.4 crore from Rs 1,017.4 crore as revenue expanded. The FY26 percentage remained below the 9.0% recorded in FY24.
Why did healthX remain loss-making at the operating level?
healthX remained EBITDA-negative because its Rs 97.5 crore gross margin did not cover Rs 84.0 crore of employee-benefit expense and Rs 79.0 crore of other expenses in FY26. EBITDA improved by Rs 13.4 crore to a loss of Rs 65.5 crore from a loss of Rs 78.9 crore in FY25. The EBITDA margin moved to negative 5.0% from negative 7.2%.
Employee-benefit expense increased by Rs 34.2 crore year on year, to Rs 84.0 crore from Rs 49.8 crore. Other expenses moved in the opposite direction, declining by Rs 20.8 crore to Rs 79.0 crore from Rs 99.8 crore. The Rs 26.8 crore increase in gross margin and lower other expenses reduced the EBITDA loss, but did not eliminate it.
healthX reported an earnings before interest and tax loss of Rs 0.4 crore in FY26, compared with a Rs 2.1 crore loss in FY25, after other income of Rs 71.6 crore and depreciation and amortisation of Rs 6.6 crore. Finance costs were Rs 0.8 crore in FY26. The loss for the year narrowed to Rs 1.4 crore from Rs 133.5 crore in FY25, when exceptional items were Rs 190.5 crore.
Got a follow-up? Ask IRIS
What does healthX’s FY26 balance sheet show?
healthX ended FY26 with total equity of Rs 765.3 crore, down Rs 99.2 crore from Rs 864.5 crore at March 2025. Other equity fell to Rs 733.5 crore from Rs 832.7 crore, while equity share capital was unchanged at Rs 31.8 crore. Total assets declined by Rs 38.6 crore to Rs 935.8 crore.
The FY26 balance sheet showed higher inventory alongside lower investments. Inventories increased by Rs 34.3 crore to Rs 144.6 crore, while investments fell by Rs 56.7 crore to Rs 518.7 crore. Cash and cash equivalents rose to Rs 30.2 crore from Rs 12.4 crore, while other current assets declined by Rs 65.2 crore to Rs 24.7 crore.
healthX’s financial liabilities increased to Rs 141.7 crore at March 2026 from Rs 87.9 crore at March 2025. The movement included Rs 22.1 crore of borrowings, compared with no borrowings in the prior year, and trade payables of Rs 86.0 crore, up from Rs 58.8 crore. Total current assets decreased to Rs 735.4 crore from Rs 807.0 crore.
Why did healthX’s operating cash outflow widen in FY26?
healthX used Rs 73.8 crore in operating activities in FY26, compared with Rs 17.3 crore used in FY25, despite the smaller reported annual loss. Operating profit before working-capital changes was negative Rs 58.7 crore, compared with negative Rs 65.5 crore in FY25. The pre-working-capital operating result improved by Rs 6.8 crore, but working-capital cash movement changed direction.
Working capital used Rs 10.8 crore of cash in FY26, compared with a Rs 52.7 crore source of cash in FY25. Cash generated from operations therefore moved to negative Rs 69.5 crore from negative Rs 12.9 crore. Direct taxes paid were Rs 4.3 crore in FY26, compared with Rs 4.5 crore in FY25, taking net operating cash use to Rs 73.8 crore.
healthX’s cash and cash equivalents still increased by Rs 17.8 crore during FY26, reaching Rs 30.2 crore at year-end from Rs 12.4 crore at the beginning of the year. Cash flow from investing activities was Rs 171.2 crore, partly offset by Rs 79.6 crore used in financing activities and the Rs 73.8 crore operating outflow. The cash-flow statement thus distinguishes the higher closing cash balance from cash generated by operations.
Conclusion
healthX’s FY26 results show that revenue and gross margin recovered after FY25, with revenue reaching Rs 1,305.9 crore and gross margin increasing to Rs 97.5 crore. However, EBITDA remained negative at Rs 65.5 crore, operating cash use widened to Rs 73.8 crore and total equity fell to Rs 765.3 crore. The reported figures therefore show improved sales and margin measures without positive operating cash generation.
The key unresolved matter in the disclosed FY26 data is whether healthX can reduce its negative operating profit and reverse the working-capital cash outflow that contributed Rs 10.8 crore of cash use. In Q2 FY27, healthX reported revenue from operations of Rs 489.1 crore, gross-margin percentage of 8.3% and an EBITDA loss of Rs 17.2 crore. Later disclosures will show whether those revenue and margin figures are accompanied by a change in operating cash flow.


